Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD
Part of paid clinical trials in Encino, California.
- Sponsor
- Clinical Testing of Beverly Hills
- Study ID
- NCT05129319
- Phase
- EARLY_PHASE1
- Status
- Completed
Conditions
- Glabellar Frown Lines
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- prabotulinumtoxinA — DRUGInjection of glabellar rhytids
Study Details
This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Jeuveau in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.
Key Dates
- First listed
- Nov 22, 2021
- Start date
- Dec 16, 2021
- Status verified
- Mar 2022
- Primary completion
- Jun 15, 2023
- Completion
- Jun 15, 2023
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: OLD (4 U per 0.1 mL)The total Jeuveau dose will be 20U divided into 5 injections. Each subject will receive a total of 0.5 mL of Jeuveau during the treatment.
- Active Comparator: COLD (4 U per 0.02 mL group)The total Jeuveau dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL of Jeuveau during the treatment.
Primary Outcome Measure
Response Duration [ Time Frame: 270 days ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Clinical Testing of Beverly Hills | Encino | California | 91436 | - |
Find similar trials in Encino, CA
By research site